PMC:7441788 / 34098-35313
Annnotations
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T132 | 70-78 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T133 | 303-311 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T134 | 524-532 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T135 | 1028-1036 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T136 | 1206-1214 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T245 | 48-49 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T246 | 826-828 | http://purl.obolibrary.org/obo/CLO_0037161 | denotes | en |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T361 | 21-23 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
| T362 | 205-207 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
| T363 | 363-365 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
| T364 | 370-380 | Chemical | denotes | macrolides | http://purl.obolibrary.org/obo/CHEBI_25106 |
| T365 | 382-394 | Chemical | denotes | azithromycin | http://purl.obolibrary.org/obo/CHEBI_2955 |
| T366 | 398-412 | Chemical | denotes | clarithromycin | http://purl.obolibrary.org/obo/CHEBI_3732 |
| T367 | 504-506 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
| T368 | 826-828 | Chemical | denotes | en | http://purl.obolibrary.org/obo/CHEBI_30347 |
| T369 | 895-897 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
| T370 | 933-935 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
| T371 | 969-979 | Chemical | denotes | macrolides | http://purl.obolibrary.org/obo/CHEBI_25106 |
| T372 | 1163-1168 | Chemical | denotes | drugs | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-sample-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T200 | 21-23 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
| T201 | 205-207 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
| T202 | 363-365 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
| T203 | 370-380 | Chemical | denotes | macrolides | http://purl.obolibrary.org/obo/CHEBI_25106 |
| T204 | 382-394 | Chemical | denotes | azithromycin | http://purl.obolibrary.org/obo/CHEBI_2955 |
| T205 | 398-412 | Chemical | denotes | clarithromycin | http://purl.obolibrary.org/obo/CHEBI_3732 |
| T206 | 504-506 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
| T207 | 895-897 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
| T208 | 933-935 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
| T209 | 969-979 | Chemical | denotes | macrolides | http://purl.obolibrary.org/obo/CHEBI_25106 |
LitCovid-sample-PD-NCBITaxon
| Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
|---|---|---|---|---|---|
| T128 | 70-78 | Species | denotes | COVID-19 | NCBItxid:2697049 |
| T129 | 303-311 | Species | denotes | COVID-19 | NCBItxid:2697049 |
| T130 | 524-532 | Species | denotes | COVID-19 | NCBItxid:2697049 |
| T131 | 1028-1036 | Species | denotes | COVID-19 | NCBItxid:2697049 |
| T132 | 1206-1214 | Species | denotes | COVID-19 | NCBItxid:2697049 |
LitCovid-sample-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T233 | 0-321 | Sentence | denotes | In summary, although CQ/HCQ appeared to exhibit a favorable effect on COVID-19 patients in some initial studies of small numbers of patients, the most recent studies with larger sample sizes revealed that CQ/HCQ exhibited no significant improvement of disease but even an increased overall mortality in COVID-19 patients. |
| T234 | 322-447 | Sentence | denotes | The studies on the combination of HCQ or CQ and macrolides (azithromycin or clarithromycin) also showed conflicting findings. |
| T235 | 448-638 | Sentence | denotes | Therefore, caution should be taken regarding the use of CQ/HCQ treatment in COVID-19 due to the uncertainty of efficacy, the potential adverse effects and the various defects in the studies. |
| T236 | 639-902 | Sentence | denotes | According to the Chinese Clinical Trial Registry (ChiCTR) (http://www.chictr.org.cn/index.aspx) and the International Clinical Trials Registry Platform (ICTRP) (https://www.who.int/ictrp/en/), currently, there are more than 200 ongoing clinical trials for CQ/HCQ. |
| T237 | 903-1065 | Sentence | denotes | Current findings suggest that CQ/HCQ alone or in combination with macrolides should not be recommended for widespread use in COVID-19 (except in clinical trials). |
| T238 | 1066-1215 | Sentence | denotes | Results from these ongoing prospective, randomized, controlled studies are required before these drugs are recommended for the treatment of COVID-19. |
LitCovid-sample-Pubtator
| Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
|---|---|---|---|---|---|
| 1234 | 79-87 | Species | denotes | patients | Tax:9606 |
| 1235 | 132-140 | Species | denotes | patients | Tax:9606 |
| 1236 | 312-320 | Species | denotes | patients | Tax:9606 |
| 1237 | 21-27 | Chemical | denotes | CQ/HCQ | |
| 1238 | 205-211 | Chemical | denotes | CQ/HCQ | |
| 1239 | 356-359 | Chemical | denotes | HCQ | MESH:D006886 |
| 1240 | 363-365 | Chemical | denotes | CQ | MESH:D002738 |
| 1241 | 370-380 | Chemical | denotes | macrolides | MESH:D018942 |
| 1242 | 382-394 | Chemical | denotes | azithromycin | MESH:D017963 |
| 1243 | 398-412 | Chemical | denotes | clarithromycin | MESH:D017291 |
| 1244 | 504-506 | Chemical | denotes | CQ | MESH:D002738 |
| 1245 | 507-510 | Chemical | denotes | HCQ | MESH:D006886 |
| 1246 | 895-897 | Chemical | denotes | CQ | MESH:D002738 |
| 1247 | 898-901 | Chemical | denotes | HCQ | MESH:D006886 |
| 1248 | 933-939 | Chemical | denotes | CQ/HCQ | |
| 1249 | 969-979 | Chemical | denotes | macrolides | MESH:D018942 |
| 1250 | 70-78 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1251 | 290-299 | Disease | denotes | mortality | MESH:D003643 |
| 1252 | 303-311 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1253 | 524-532 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1254 | 1028-1036 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1255 | 1206-1214 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 689 | 898-901 | Chemical | denotes | HCQ | MESH:D006886 |
LitCovid-sample-PD-IDO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T140 | 252-259 | http://purl.obolibrary.org/obo/OGMS_0000031 | denotes | disease |
LitCovid-sample-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T125 | 70-78 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T126 | 303-311 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T127 | 524-532 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T128 | 1028-1036 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T129 | 1206-1214 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1234 | 79-87 | Species | denotes | patients | Tax:9606 |
| 1235 | 132-140 | Species | denotes | patients | Tax:9606 |
| 1236 | 312-320 | Species | denotes | patients | Tax:9606 |
| 1237 | 21-27 | Chemical | denotes | CQ/HCQ | |
| 1238 | 205-211 | Chemical | denotes | CQ/HCQ | |
| 1239 | 356-359 | Chemical | denotes | HCQ | MESH:D006886 |
| 1240 | 363-365 | Chemical | denotes | CQ | MESH:D002738 |
| 1241 | 370-380 | Chemical | denotes | macrolides | MESH:D018942 |
| 1242 | 382-394 | Chemical | denotes | azithromycin | MESH:D017963 |
| 1243 | 398-412 | Chemical | denotes | clarithromycin | MESH:D017291 |
| 1244 | 504-506 | Chemical | denotes | CQ | MESH:D002738 |
| 1245 | 507-510 | Chemical | denotes | HCQ | MESH:D006886 |
| 1246 | 895-897 | Chemical | denotes | CQ | MESH:D002738 |
| 1247 | 898-901 | Chemical | denotes | HCQ | MESH:D006886 |
| 1248 | 933-939 | Chemical | denotes | CQ/HCQ | |
| 1249 | 969-979 | Chemical | denotes | macrolides | MESH:D018942 |
| 1250 | 70-78 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1251 | 290-299 | Disease | denotes | mortality | MESH:D003643 |
| 1252 | 303-311 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1253 | 524-532 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1254 | 1028-1036 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1255 | 1206-1214 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T233 | 0-321 | Sentence | denotes | In summary, although CQ/HCQ appeared to exhibit a favorable effect on COVID-19 patients in some initial studies of small numbers of patients, the most recent studies with larger sample sizes revealed that CQ/HCQ exhibited no significant improvement of disease but even an increased overall mortality in COVID-19 patients. |
| T234 | 322-447 | Sentence | denotes | The studies on the combination of HCQ or CQ and macrolides (azithromycin or clarithromycin) also showed conflicting findings. |
| T235 | 448-638 | Sentence | denotes | Therefore, caution should be taken regarding the use of CQ/HCQ treatment in COVID-19 due to the uncertainty of efficacy, the potential adverse effects and the various defects in the studies. |
| T236 | 639-902 | Sentence | denotes | According to the Chinese Clinical Trial Registry (ChiCTR) (http://www.chictr.org.cn/index.aspx) and the International Clinical Trials Registry Platform (ICTRP) (https://www.who.int/ictrp/en/), currently, there are more than 200 ongoing clinical trials for CQ/HCQ. |
| T237 | 903-1065 | Sentence | denotes | Current findings suggest that CQ/HCQ alone or in combination with macrolides should not be recommended for widespread use in COVID-19 (except in clinical trials). |
| T238 | 1066-1215 | Sentence | denotes | Results from these ongoing prospective, randomized, controlled studies are required before these drugs are recommended for the treatment of COVID-19. |